Skip to Content


Agency Information Collection Activities; Proposed Collection; Comment Request; Mammography Quality Standards Act Requirements

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on Start Printed Page 13682the estimated reporting, recordkeeping, and third-party disclosure burden associated with the Mammography Quality Standards Act requirements.


Submit either electronic or written comments on the collection of information by April 29, 2013.


Submit electronic comments on the collection of information to Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

Start Further Info


Daniel Gittleson, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-5156,

End Further Info End Preamble Start Supplemental Information


Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Mammography Quality Standards Act Requirements—21 CFR Part 900 (OMB Control Number 0910-0309)—Extension

The Mammography Quality Standards Act requires the establishment of a Federal certification and inspection program for mammography facilities; regulations and standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. The intent of these regulations is to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body (AB). This requires undergoing a review of their clinical images and providing the AB with information showing that they meet the equipment, personnel, quality assurance and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer complaint mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA-approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis.

The following sections of Title 21 of the Code of Federal Regulations (CFR) are not included in the burden tables because they are considered usual and customary practice and were part of the standard of care prior to the implementation of the regulations. Therefore, they resulted in no additional burden: 21 CFR 900.12(c)(1) and (c)(3) and 21 CFR 900.3(f)(1). Section 900.24(c) was also not included in the burden tables because if a certifying State had its approval withdrawn, FDA would take over certifying authority for the affected facilities. Because FDA already has all the certifying State's electronic records, there wouldn't be an additional reporting burden.

We have rounded numbers in the “Total Hours” column in all three burden tables. (Where the number was a portion of one hour, it has been rounded to 1 hour. All other “Total Hours” have been rounded to the nearest whole number.)

We do not expect any respondents for § 900.3(c) because all four ABs are approved until April 2020.

FDA estimates the burden of this collection of information as follows:

Table 1—Estimated Annual Reporting Burden

Activity/21 CFR Section/FDA Form No.Number of respondentsNumber of responses per respondentTotal annual responsesAverage burden per responseTotal hours 1Total capital costsTotal operating & maintenance costs
Notification of intent to become an AB—900.3(b)(1)0.3310.3311
Application for approval as an AB; full 2—900.3(b)(3)0.3310.33320106$10,000
Application for approval as an AB; limited 3—900.3(b)(3)51530150
AB renewal of approval—900.3(c)010151
AB application deficiencies—900.3(d)(2)0.110.1303
AB resubmission of denied applications—900.3(d)(5)0.110.1303
Letter of intent to relinquish accreditation authority—900.3(e)0.110.111
Summary report describing all facility assessments—900.4(f)330133072,310$77,600
AB reporting to FDA; facility 4—900.4(h)8,65418,65418,6544,327
AB reporting to FDA; AB 5—900.4(h)5151050
AB financial records—900.4(i)(2)1111616
Start Printed Page 13683
Former AB new application—900.6(c)(1)0.110.1606
Reconsideration of accreditation following appeal—900.15(d)(3)(ii)11122
Application for alternative standard—900.18(c)21224
Alternative standard amendment—900.18(e)10110110
Certification agency application—900.21(b)0.3310.33320106$208
Certification agency application deficiencies—900.21(c)(2)0.110.1303
Certification electronic data transmission—900.22(h)520010000.08383$30,000
Changes to standards—900.22(i)2123060$20
Certification agency minor deficiencies—900.24(b)1113030
Appeal of adverse action taken by FDA—900.25(a)0.210.2163
Inspection fee exemption—FDA Form 342270017000.25175
1 Total hours have been rounded.
2 One time burden.
3 Refers to accreditation bodies applying to accredit specific full-field digital mammography units.
4 Refers to the facility component of the burden for this requirement.
5 Refers to the AB component of the burden for this requirement.

Table 2—Estimated Annual Recordkeeping Burden

Activity/21 CFR SectionNo. of recordkeepersNo. of records per recordkeeperTotal annual recordsAverage burden per recordkeepingTotal hours 1Total capital costsTotal operating and maintenance costs
AB transfer of facility records—900.3(f)(1)0.110.101
Consumer complaints system; AB—900.4(g)51515
Documentation of interpreting physician initial requirements—900.12(a)(1)(i)(B)(2)871878696
Documentation of interpreting physician personnel requirements—900.12(a)(4)8,654434,616134,616
Permanent medical record—900.12(c)(4)8,65418,65418,654$28,000
Procedures for cleaning equipment—900.12(e)(13)8,65452450,0080.08337,351
Audit program—900.12(f)8,65418,65416138,464
Consumer complaints system; facility—900.12(h)(2)8,654217,308117,308
Certification agency conflict of interest—900.22(a)51515
Processes for suspension and revocation of certificates—900.22(d)51515
Processes for appeals—900.22(e)51515
Processes for additional mammography review—900.22(f)51515
Processes for patient notifications—900.22(g)31313$30
Evaluation of certification agency—900.2351520100
1 Total hours have been rounded.
Start Printed Page 13684

Table 3—Estimated Annual Third-Party Disclosures 1

Activity/21 CFR SectionNumber of respondentsNumber of disclosures per respondentTotal annual disclosuresAverage burden per disclosureTotal hours 2Total operating and maintenance costs
Notification of facilities that AB relinquishes its accreditation—900.3(f)(2)0.110.120020$50
Clinical images; facility 2—900.4(c), 900.11(b)(1), and 900.11(b)(2)2,88512,8851.444,154
Clinical images; AB 3—900.4(c)5154162,080230,773
Phantom images; facility 2—900.4(d), 900.11(b)(1), and 900.11(b)(2)2,88512,8850.722,077
Phantom images; AB 3—900.4(d)5152081,040
Annual equipment evaluation and survey; facility 2—900.4(e), 900.11(b)(1), and 900.11(b)(2)8,65418,65418,6548,654
Annual equipment evaluation and survey; AB 3—900.4(e)5151,7308,650
Provisional mammography facility certificate extension application—900.11(b)(3)0100.51
Mammography facility certificate reinstatement application—900.11(c)312131251,56024,000,000
Lay summary of examination—900.12(c)(2)8,6545,08544,005,5900.0833,652,464
Lay summary of examination; patient refusal 4—900.12(c)(2)871870.544
Report of unresolved serious complaints—900.12(h)(4)20120120
Information regarding compromised quality; facility 2—900.12(j)(1)201202004,000300
Information regarding compromised quality; AB 3—900.12(j)(1)201203206,400600
Patient notification of serious risk—900.12(j)(2)51510050019,375
Reconsideration of accreditation—900.15(c)515210
Notification of requirement to correct major deficiencies—900.24(a)0.410.42008068
Notification of loss of approval; major deficiencies—900.24(a)(2)0.1510.151001525.50
Notification of probationary status—900.24(b)(1)0.310.32006051
Notification of loss of approval; minor deficiencies—900.24(b)(3)0.1510.151001525.50
1 There are no capital costs associated with this collection of information.
2 Total hours have been rounded.
Start Signature

Dated: February 22, 2013.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2013-04677 Filed 2-27-13; 8:45 am]